- Home
- RELX vs ZTS Comparison
RELX vs ZTS Comparison
Compare RELX & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RELX
- ZTS
- Stock Information
- Founded
- RELX 1903
- ZTS 1952
- Country
- RELX United Kingdom
- ZTS United States
- Employees
- RELX N/A
- ZTS N/A
- Industry
- RELX Business Services
- ZTS Biotechnology: Pharmaceutical Preparations
- Sector
- RELX Consumer Discretionary
- ZTS Health Care
- Exchange
- RELX Nasdaq
- ZTS Nasdaq
- Market Cap
- RELX 84.1B
- ZTS 80.4B
- IPO Year
- RELX N/A
- ZTS 2013
- Fundamental
- Price
- RELX $49.54
- ZTS $167.47
- Analyst Decision
- RELX Strong Buy
- ZTS Strong Buy
- Analyst Count
- RELX 1
- ZTS 8
- Target Price
- RELX N/A
- ZTS $215.38
- AVG Volume (30 Days)
- RELX 681.4K
- ZTS 2.7M
- Earning Date
- RELX 02-13-2025
- ZTS 02-13-2025
- Dividend Yield
- RELX 1.53%
- ZTS 1.03%
- EPS Growth
- RELX 8.89
- ZTS 8.38
- EPS
- RELX 1.26
- ZTS 5.32
- Revenue
- RELX $11,757,048,799.00
- ZTS $9,152,000,000.00
- Revenue This Year
- RELX $7.35
- ZTS $9.48
- Revenue Next Year
- RELX $5.49
- ZTS $4.87
- P/E Ratio
- RELX $37.81
- ZTS $31.51
- Revenue Growth
- RELX 2.42
- ZTS 9.33
- 52 Week Low
- RELX $40.25
- ZTS $144.80
- 52 Week High
- RELX $49.57
- ZTS $200.53
- Technical
- Relative Strength Index (RSI)
- RELX 74.07
- ZTS 49.25
- Support Level
- RELX $45.38
- ZTS $161.58
- Resistance Level
- RELX $46.82
- ZTS $169.78
- Average True Range (ATR)
- RELX 0.45
- ZTS 3.58
- MACD
- RELX 0.40
- ZTS 0.87
- Stochastic Oscillator
- RELX 99.35
- ZTS 74.86
About RELX RELX PLC PLC
RELX is a global provider of information-based analytics and decision tools for professional and business customers in various industries. The company serves sectors such as science and medical research, risk management, and legal. In addition, RELX organizes large-scale digital and face-to-face events such as industry trade shows. Around 60% of revenue is generated in North America and about 20% in Europe.
About ZTS Zoetis Inc.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.